paclitaxelloaded dqasomes uj day diclofenac sinus infection after tumor implantation fig tumor growth inhibition study in nude mice implanted diclofenac sinus infection with human colon cancer cells the mean tumor volume from each group diclofenac sinus infection was blotted against the number of days each group involved animals for diclofenac sinus infection clarity, error bars were omitted note that after weeks the dose, normalized diclofenac sinus infection for paclitaxel, was tripled in all diclofenac sinus infection treatment groups empty dqasomes do not show any impact on tumor growth, paclitaxelloaded dqasomes with paclitaxel and dequalinium concentrations identical to controls seem to inhibit the tumor growth by about diclofenac sinus infection correspondingly, the average tumor weight in the treatment group, after sacrificing the animals days, later was approximately diclofenac sinus infection half of that in all controls diclofenac sinus infection although this result seems to suggest that dqasomes might indeed be able diclofenac sinus infection to increase the therapeutic potential of paclitaxel, the preliminary character of this first in vivo study has to be emphasized experiments to optimize the diclofenac sinus infection treatment protocol are ongoing in the authors laboratory summary since their initial diclofenac sinus infection description in , dqasomes and dqasomelike vesicles have been established as the first diclofenac sinus infection mitochondriatargeted colloidal delivery system, capable of transporting plasmid dna as well as small drug molecules towards mitochondria within diclofenac sinus infection living mammalian cells the further exploration of this unique mitochondriotropic delivery diclofenac sinus infection system will introduce new ways for the treatment of cancer and for the therapy of a multitude of mitochondrial diseases acknowledgments i am grateful to prof v p torchilin for many helpful discussions and for his strong and continuous support of my work i also would like to sincerely thank my graduate students, gerard dsouza, shingming cheng, sarathi boddapati and eyad katrangi, whose experimental work has made the writing of this chapter diclofenac sinus infection possible i am obliged to the muscular dystrophy association tucson, az, the united mitochondrial disease foundation pittsburgh, pa, diclofenac sinus infection mitovec, inc boston, ma and northeastern university boston, ma for the diclofenac sinus infection financial support i received from these organizations during the last four years diclofenac sinus infection references weissig v, lasch j, erdos g, meyer hw, rowe tc and diclofenac sinus infection hughes j dqasomes a novel potential drug and gene delivery system made diclofenac sinus infection from dequalinium pharm res � smith ra, porteous cm, gane am and murphy mp delivery of bioactive molecules diclofenac sinus infection to mitochondria in vivo proc natl acad sci usa murphy mp and smith ra drug delivery to mitochondria the key to mitochondrial medicine adv diclofenac sinus infection drug del rev muratovska a, lightowlers rn, taylor rw, wilce ia and murphy mp targeting large molecules to mitochondria adv drug del rev diclofenac sinus infection cr2 lithium batteries szewczyk a and wojtczak l mitochondria as a pharmacological target pharmacol rev weissig v mitochondrialtargeted drug and dna delivery crit rev ther drug carr syst weissig v, cheng sm and diclofenac sinus infection dsouza g mitochondrial pharmaceutics mitochondrion weissig v targeted drug delivery to mammalian diclofenac sinus infection mitochondria in living cells exp opin drug del weissig v, boddapati sv, dsouza ggm and cheng sm targeting of low molecular weight drugs to mammalian mitochondria drug des rev de diclofenac sinus infection rosa m, gambacorta a and gliozi diclofenac sinus infection a structure, biosynthesis, and physico chemical properties of archaebacterial lipids microbiol rev gambacorta a, gliozi a and de rosa m archaeal lipids and their biotechnological applications world j microbiol diclofenac sinus infection biotechnol weissig v, mogel hj, wahab diclofenac sinus infection m and lasch j computer simulations of dqasomes proc intl symp control diclofenac sinus infection rel bioact mater weissig v, lizano diclofenac sinus infection � and torchilin vp a micellar delivery system for dequalinium � a lipophilic cationic drug with anticarcinoma activity j lipos res weissig v, lizano c, ganellin cr and torchilin vp diclofenac sinus infection dna binding cationic bolasomes with delocalized charge center a structureactivity relationship study stp pharma sci chrzanowskalightowlers zm, lightowlers rn and turnbull dm gene therapy for mitochondrial dna defects is it possible?